Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer
(MedPage Today) -- A first-in-class bispecific antibody achieved durable responses in a fourth of patients with advanced small cell lung cancer (SCLC) and disease control in more than half, a preliminary clinical trial showed. Tarlatamab, targeting... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 2, 2023 Category: Hematology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

The history of Martin Luther King Jr. Day
On Monday, Jan. 16, Americans observe Martin Luther King Jr. Day, a federal holiday honoring Dr. Martin Luther King Jr.'s legacy as a Civil Rights movement leader and his lifelong dedication to community service. While the whole nation now observes the holiday, the path to designating a day to…#conyers #ralphabernathy #jimmycarter #robertelee #ihaveadream #kingmemorialcenter #sclc #martinlutherking #corettascottking #johnlewis (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2023 Category: Consumer Health News Source Type: news

cfDNA and Circulating Tumor Cells as Biomarkers in SCLC cfDNA and Circulating Tumor Cells as Biomarkers in SCLC
A new study explores the potential prognostic value of these biomarkers in newly diagnosed small cell lung cancer patients.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq  If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news

Adjuvant Treatment for Incidentally Resected SCLC Adjuvant Treatment for Incidentally Resected SCLC
Should salvage adjuvant therapy be considered for small cell lung cancer patients after incidental surgical resection?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Apatinib as Second or Later-Line Therapy in Extensive SCLC Apatinib as Second or Later-Line Therapy in Extensive SCLC
Could apatinib be considered a safe and effective option for extensive-stage small cell lung cancer patients who fail to respond to first-line chemotherapy?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Serplulimab Ups Survival in SCLC, but Where Does It Fit In? Serplulimab Ups Survival in SCLC, but Where Does It Fit In?
The new PD-1 inhibitor from China yielded positive results in a phase 3 trial, and a further trial in the US is now planned to bolster prospects for FDA approval.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 5, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Gene Mutations May Drive Lung Cancer in Never-Smokers Gene Mutations May Drive Lung Cancer in Never-Smokers
A new retrospective analysis suggests small cell lung cancer (SCLC) has a different genomic profile among smokers than nonsmokers.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo
(MedPage Today) -- VIENNA -- Long-term results from the phase III KEYNOTE-604 trial appeared to strengthen the case of pembrolizumab (Keytruda) combined with platinum etoposide as a first-line treatment for patients with extensive-stage small cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 12, 2022 Category: Hematology Source Type: news

Roche ’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results
IMscin001 study showed non-inferior levels of cancer immunotherapyTecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancerAdministered under the skin, the subcutaneous formulation reduces time spent receiving treatment to just minutes, compared with up to an hour for IV infusionData will be submitted to health authorities globally, including the US Food and Drug Administration and European Medicines AgencyBasel, 2 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMscin001 study evaluating a subcutaneous form...
Source: Roche Media News - August 2, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancer
(MedPage Today) -- CHICAGO -- Combining the novel human anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) plus chemotherapy failed to improve outcomes in patients with untreated extensive-stage small cell lung cancer (SCLC... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news